A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex

Journal of Virology

Volumn 89, Issue 9, 2015, Pages 4827-4836

  Lin, Min Hsuan ^a   Apolloni, Ann ^a   Cutillas, Vincent ^a,d   Sivakumaran, Haran ^a   Martin, Sally ^b   Li, Dongsheng ^a   Wei, Ting ^a   Wang, Rui ^a,e   Jin, Hongping ^a   Spann, Kirsten ^c   Harrich, David ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d MCGILL UNIVERSITY   (Canada)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NULLBASIC; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; MUTANT PROTEIN; PROTEIN BINDING; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; ENZYME INHIBITION; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INTERFEROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION; VIRION; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS TRANSCRIPTION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CENTRIFUGATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CENTRIFUGATION; HIV REVERSE TRANSCRIPTASE; HIV-1; IMMUNOPRECIPITATION; MUTANT PROTEINS; PROTEIN BINDING; REVERSE TRANSCRIPTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84928551972     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03440-14     Document Type: Article

References (53)

1. Hu WS, Hughes SH. 2012. HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2:a006882. http://dx.doi.org/10.1101/cshperspect.a006882.
2. Warrilow D, Tachedjian G, Harrich D. 2009. Maturation of the HIV reverse transcription complex: putting the jigsaw together. Rev Med Virol 19:324-337. http://dx.doi.org/10.1002/rmv.627.
3. Warren K, Wei T, Li D, Qin F, Warrilow D, Lin MH, Sivakumaran H, Apolloni A, Abbott CM, Jones A, Anderson JL, Harrich D. 2012. Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors. Proc Natl Acad Sci USA 109:9587-9592. http://dx.doi.org/10.1073/pnas.1204673109.
4. Warren K, Warrilow D, Meredith L, Harrich D. 2009. Reverse transcriptase and cellular factors: regulators of HIV-1 reverse transcription. Viruses 1:873-894. http://dx.doi.org/10.3390/v1030873.
5. Karn J, Stoltzfus CM. 2012. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med 2:a006916. http://dx.doi.org/10.1101/cshperspect.a006916.
6. Chiu YL, Coronel E, Ho CK, Shuman S, Rana TM. 2001. HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA. J Biol Chem 276:12959-12966. http://dx.doi.org/10.1074/jbc. M007901200.
7. Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB. 1997. Tat is required for efficient HIV-1 reverse transcription. EMBOJ 16:1224-1235. http://dx.doi.org/10.1093/emboj/16.6.1224.
8. Apolloni A, Meredith LW, Suhrbier A, Kiernan R, Harrich D. 2007. The HIV-1 Tat protein stimulates reverse transcription in vitro. Curr HIV Res 5:473-483. http://dx.doi.org/10.2174/157016207781662443.
9. Kameoka M, Morgan M, Binette M, Russell RS, Rong L, Guo X, Mouland A, Kleiman L, Liang C, Wainberg MA. 2002. The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. J Virol 76:3637-3645. http://dx.doi.org/10.1128/JVI.76.8.3637-3645.2002.
10. Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D. 2009. Potent inhibition of HIV-1 replication by a Tat mutant. PLoS One 4:e7769. http://dx.doi.org/10.1371/journal.pone.0007769.
11. Ulich C, Dunne A, Parry E, Hooker CW, Gaynor RB, Harrich D. 1999. Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. J Virol 73:2499-2508.
12. Hooker CW, Scott J, Apolloni A, Parry E, Harrich D. 2002. Human immunodeficiency virus type 1 reverse transcription is stimulated by tat from other lentiviruses. Virology 300:226-235. http://dx.doi.org/10.1006/viro.2002.1554.
13. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Jr, Sowder RC, II, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE. 2006. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80:9039-9052. http://dx.doi.org/10.1128/JVI.01013-06.
14. Apolloni A, Lin MH, Sivakumaran H, Li D, Kershaw MH, Harrich D. 2013. A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells. Hum Gene Ther 24:270-282. http://dx.doi.org/10.1089/hgtb.2012.129.
15. Lin MH, Sivakumaran H, Apolloni A, Wei T, Jans DA, Harrich D. 2012. Nullbasic, a potent anti-HIV Tat mutant, induces CRM1-dependent disruption of HIV Rev trafficking. PLoS One 7:e51466. http://dx.doi.org/10.1371/journal.pone.0051466.
16. Sivakumaran H, Cutillas V, Harrich D. 2013. Revisiting transdominant-negative proteins in HIV gene therapy. Future Virol 8:757-768. http://dx.doi.org/10.2217/fvl.13.65.
17. Pearson L, Garcia J, Wu F, Modesti N, Nelson J, Gaynor R. 1990. A transdominant Tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 87:5079-5083. http://dx.doi.org/10.1073/pnas.87.13.5079.
18. Modesti N, Garcia J, Debouck C, Peterlin M, Gaynor R. 1991. Transdominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 3:759-768.
19. Herskowitz I. 1987. Functional inactivation of genes by dominant negative mutations. Nature 329:219-222. http://dx.doi.org/10.1038/329219a0.
20. Orsini MJ, Debouck CM. 1996. Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm. J Virol 70:8055-8063.
21. Jones KA. 1997. Taking a new TAK on tat transactivation. Genes Dev 11:2593-2599. http://dx.doi.org/10.1101/gad.11.20.2593.
22. Ulich C, Harrich D, Estes P, Gaynor RB. 1996. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J Virol 70:4871-4876.
23. Malim MH, McCarn DF, Tiley LS, Cullen BR. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol 65:4248-4254.
24. Pollard VW, Malim MH. 1998. The HIV-1 Rev protein. Annu Rev Microbiol 52:491-532. http://dx.doi.org/10.1146/annurev.micro.52.1.491.
25. Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K. 2000. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 11:2403-2413. http://dx.doi.org/10.1089/104303400750038507.
26. Dettenhofer M, Yu XF. 1999. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol 73:1460-1467.
27. Ott DE. 2009. Purification of HIV-1 virions by subtilisin digestion or CD45 immunoaffinity depletion for biochemical studies. Methods Mol Biol 485:15-25.
28. Fassati A. 2009. Methods of preparation and analysis of intracellular reverse transcription complexes. Methods Mol Biol 485:107-119. http://dx.doi.org/10.1007/978-1-59745-170-3_2.
29. Warrilow D, Warren K, Harrich D. 2010. Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro. PLoS One 5:e13229. http://dx.doi.org/10.1371/journal.pone.0013229.
30. Aiken C. 2009. Cell-free assays for HIV-1 uncoating. Methods Mol Biol 485:41-53. http://dx.doi.org/10.1007/978-1-59745-170-3_4.
31. Martin S, Harper CB, May LM, Coulson EJ, Meunier FA, Osborne SL. 2013. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death. PLoS One 8:e60152. http://dx.doi.org/10.1371/journal.pone.0060152.
32. Herschhorn A, Oz-Gleenberg I, Hizi A. 2008. Quantitative analysis of the interactions between HIV-1 integrase and retroviral reverse transcriptases. Biochem J 412:163-170. http://dx.doi.org/10.1042/BJ20071279.
33. Fassati A, Goff SP. 2001. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75:3626-3635. http://dx.doi.org/10.1128/JVI.75.8.3626-3635.2001.
34. Nermut MV, Fassati A. 2003. Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol 77:8196-8206. http://dx.doi.org/10.1128/JVI.77.15.8196-8206.2003.
35. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76:5667-5677. http://dx.doi.org/10.1128/JVI.76.11.5667-5677.2002.
36. Hulme AE, Perez O, Hope TJ. 2011. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci USA 108:9975-9980. http://dx.doi.org/10.1073/pnas.1014522108.
37. Grigorov B, Bocquin A, Gabus C, Avilov S, Mely Y, Agopian A, Divita G, Gottikh M, Witvrouw M, Darlix JL. 2011. Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex. Nucleic Acids Res 39:5586-5596. http://dx.doi.org/10.1093/nar/gkr117.
38. Iordanskiy S, Berro R, Altieri M, Kashanchi F, Bukrinsky M. 2006. Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin. Retrovirology 3:4. http://dx.doi.org/10.1186/1742-4690-3-4.
39. Carr JM, Coolen C, Davis AJ, Burrell CJ, Li P. 2008. Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription. Virology 372:147-156. http://dx.doi.org/10.1016/j.virol.2007.10.041.
40. Apolloni A, Hooker CW, Mak J, Harrich D. 2003. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol 77:9912-9921. http://dx.doi.org/10.1128/JVI.77.18.9912-9921.2003.
41. Boudier C, Humbert N, Chaminade F, Chen Y, de Rocquigny H, Godet J, Mauffret O, Fosse P, Mely Y. 2014. Dynamic interactions of the HIV-1 Tat with nucleic acids are critical for Tat activity in reverse transcription. Nucleic Acids Res 42:1065-1078. http://dx.doi.org/10.1093/nar/gkt934.
42. Godet J, Boudier C, Humbert N, Ivanyi-Nagy R, Darlix JL, Mely Y. 2012. Comparative nucleic acid chaperone properties of the nucleocapsid protein NCp7 and Tat protein of HIV-1. Virus Res 169:349-360. http://dx.doi.org/10.1016/j.virusres.2012.06.021.
43. Boudier C, Storchak R, Sharma KK, Didier P, Follenius-Wund A, Muller S, Darlix JL, Mely Y. 2010. The mechanism of HIV-1 Tat-directed nucleic acid annealing supports its role in reverse transcription. J Mol Biol 400:487-501. http://dx.doi.org/10.1016/j.jmb.2010.05.033.
44. Kameoka M, Rong L, Gotte M, Liang C, Russell RS, Wainberg MA. 2001. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol 75:2675-2683. http://dx.doi.org/10.1128/JVI.75.6.2675-2683.2001.
45. Guo X, Kameoka M, Wei X, Roques B, Gotte M, Liang C, Wainberg MA. 2003. Suppression of an intrinsic strand transfer activity of HIV-1 Tat protein by its second-exon sequences. Virology 307:154-163. http://dx.doi.org/10.1016/S0042-6822(02)00068-5.
46. Feng S, Holland EC. 1988. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165-167. http://dx.doi.org/10.1038/334165a0.
47. Berkhout B, Jeang KT. 1989. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J Virol 63:5501-5504.
48. Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB. 1989. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 8:765-778.
49. Wilkinson KA, Gorelick RJ, Vasa SM, Guex N, Rein A, Mathews DH, Giddings MC, Weeks KM. 2008. High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. PLoS Biol 6:e96. http://dx.doi.org/10.1371/journal.pbio.0060096.
50. Kuciak M, Gabus C, Ivanyi-Nagy R, Semrad K, Storchak R, Chaloin O, Muller S, Mely Y, Darlix JL. 2008. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Res 36:3389-3400. http://dx.doi.org/10.1093/nar/gkn177.
51. Doetsch M, Furtig B, Gstrein T, Stampfl S, Schroeder R. 2011. The RNA annealing mechanism of the HIV-1 Tat peptide: conversion of the RNA into an annealing-competent conformation. Nucleic Acids Res 39:4405-4418. http://dx.doi.org/10.1093/nar/gkq1339.
52. Lanchy JM, Ehresmann C, Le Grice SF, Ehresmann B, Marquet R. 1996. Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription. EMBO J 15:7178-7187.
53. Van Duyne R, Kehn-Hall K, Carpio L, Kashanchi F. 2009. Cell-typespecific proteome and interactome: using HIV-1 Tat as a test case. Expert Rev Proteomics 6:515-526. http://dx.doi.org/10.1586/epr.09.73.